[HTML][HTML] Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue
T Bärnthaler, A Theiler, D Zabini, S Trautmann… - Journal of Allergy and …, 2020 - Elsevier
Background Idiopathic pulmonary fibrosis (IPF) is a disease with high 5-year mortality and
few therapeutic options. Prostaglandin (PG) E 2 exhibits antifibrotic properties and is
reduced in bronchoalveolar lavage from patients with IPF. 15-Prostaglandin dehydrogenase
(15-PGDH) is the key enzyme in PGE 2 metabolism under the control of TGF-β and
microRNA 218. Objective We sought to investigate the expression of 15-PGDH in IPF and
the therapeutic potential of a specific inhibitor of this enzyme in a mouse model and human …
few therapeutic options. Prostaglandin (PG) E 2 exhibits antifibrotic properties and is
reduced in bronchoalveolar lavage from patients with IPF. 15-Prostaglandin dehydrogenase
(15-PGDH) is the key enzyme in PGE 2 metabolism under the control of TGF-β and
microRNA 218. Objective We sought to investigate the expression of 15-PGDH in IPF and
the therapeutic potential of a specific inhibitor of this enzyme in a mouse model and human …